DME Capital Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History
Bought
Maintained
Sold
Other funds holding LKFT
GS
TCM
MAP
EC
PM
SBH
DME Capital Management's LKFT Position: Q1 2026 in Review
DME Capital Management held its Lakefront Biotherapeutics American Depositary Shares (LKFT) position steady in Q1 2026 at 482,746 shares worth $14.5M. The position accounts for 0.45% of the portfolio, ranked #37.
DME Capital Management first reported a position in LKFT in Q1 2024 and has held it in 9 quarters since. The position peaked at $16.7M in Q3 2025. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.
- DME Capital Management held 482,746 shares of Lakefront Biotherapeutics American Depositary Shares worth $14.5M as of Q1 2026.
- DME Capital Management left its Lakefront Biotherapeutics American Depositary Shares share count unchanged in Q1 2026.
- Lakefront Biotherapeutics American Depositary Shares made up 0.45% of DME Capital Management's portfolio in Q1 2026, its #37 holding.
- DME Capital Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2024 and has held it in 9 quarters since.
- DME Capital Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $16.7M in Q3 2025.
- 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.
Based on DME Capital Management's 13F filing for Q1 2026, filed 15 May 2026.